Bottom line: Two well-performed outcomes studies addressing the effectiveness of INCS as monotherapy for the treatment of acute rhinosinusitis produced differing results.2,3 The authors of this review felt that data remain insufficient to recommend the use of an INCS for this purpose. However, Cochrane evaluated the same data and concluded that current evidence supports the use of INCS as adjunctive or monotherapy for acute rhinosinusitis.1
Explore this issue:July 2010
Citation: Venekamp RP, Sachs APE, Bonten MJ, et al. Intranasal corticosteroid monotherapy in acute rhinosinusitis: an evidence-based case report. Otolaryngol Head Neck Surg. 2010;142(6):783-788.
- Zalmanovici A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev. 2009;(4):CD005149.
- Williamson IG, Rumsby K, Benge S, et al. Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis: a randomized controlled trial. JAMA. 2007;298(21):2487-2496.
- Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116(6):1289-1295.
—Reviewed by Bradley F. Marple, MD